I'm pleased and honored to be in touch with the staff and clients of Misr Pharmaceuticals Company 

The results of transactions in the fiscal year 2022/2023 have resulted in growth compared to the fiscal year 2021/2022 as follows: -

• Revenues from operations reached LE 479 million during the fiscal year 2022/2023 compared to LE 411 million recorded in the previous fiscal year, with an increase of LE 68 million and by rate of 17 %

• The value of the net sales (local and export) amounted to LE 471 million during the fiscal year 2022/2023 compared to LE 406 million recorded in the previous fiscal year, with an increase of LE 65 million and by rate of 16%

• The value of exports amounted to LE 73.4 million during the fiscal year 2022/2023 compared to LE 38 million recorded in the previous fiscal year, with an increase  of LE 35.4million and by rate of 93%.

• The value of production at the selling price amounted to LE 490.3 million during the fiscal year 2022/2023 compared to LE 416 million recorded in the previous fiscal year, with an increase of LE 74.3 million and by rate of 18%.

• The value of net profit before tax deduction amounted LE 57.4 million during the fiscal year 2022/2023 compared to LE 60.3 million (net profit) recorded in the previous fiscal year( 57.4 represents 12% of   Revenues)

 Dr / Khaled Atef Elmounayri